Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration-Reference-Cited by-同舟云学术

Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration

Published:2020-11-17 Issue:5 Volume:259 Page:1191-1198
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Sawada Tomoko^ORCID, ,Yasukawa Tsutomu,Imaizumi Hiroko,Matsubara Hisashi,Kimura Kazuhiro,Terasaki Hiroto,Ishikawa Hiroto,Murakami Tomoya,Takeuchi Masaru,Mitamura Yoshinori,Yamashita Mariko,Takamura Yoshihiro,Murata Toshinori,Kogo Jiro,Ohji Masahito

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s00417-020-05005-y.pdf

Reference14 articles.

1. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pseudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study (2017) Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 5:e1221–e1234. https://doi.org/10.1016/S2214-109X(17)30393-5

2. Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahay-Mazza C, Fajnkuchen F, Nghiem-Buffet S, Quentel G, Tadayoni R (2013) Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol 251:2499–2503. https://doi.org/10.1007/s00417-013-2338-z

3. Westborg I, Granstam E, Rosso A, Albecht K, Lövestam-Adrian M (2017) Treatment for neovascular age-related macular degeneration n Sweden: outcomes at seven years in the Swedish Macula Register. Acta Ophthalmol 95:787–795. https://doi.org/10.1111/aos.13539

4. Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL (2020) Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol 98:132–138. https://doi.org/10.1111/aos.14183

5. Talks JS, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N, McKibbin M, Baily C, Mahmood S, for the United Kingdom Aflibercept Users Group (2016) First-year visual acuity outcomes of providing aflibercept according to the VIEW Study protocol for age-related macular degeneration. Ophthalmology 123:337–343. https://doi.org/10.1016/j.ophtha.2015.09.039

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration;Scientific Reports;2023-06-30

2. Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration;Japanese Journal of Ophthalmology;2023-03

3. The Antimicrobial Photoinactivation Effect on Escherichia coli through the Action of Inverted Cationic Porphyrin–Cyclodextrin Conjugates;Microorganisms;2022-03-26

4. Clinical characteristics and pachychoroid incidence in Japanese patients with neovascular age-related macular degeneration;Scientific Reports;2022-03-16